Oral vasoconstrictors in perennial non-allergic rhinitis.
Nasal airway resistance and nasal symptoms were evaluated in patients with perennial non-allergic rhinitis before and after vasoconstrictory drugs and placebo taken orally. The patients were partly selected; those suffering mainly from nasal obstruction being tested. Phenylpropanolamine (PPA) in a dose of 100 mg in a sustained-release preparation clearly decreased the nasal airway resistance measured rhinomanometrically. PPA in a dose of 50 mg and combined with an antihistamine had no obvious decongesting effect. Placebo and dihydroergotamine (DHE) in a dose of 5 mg did not decrease the nasal airway resistance PPA (100 mg) and the combined preparation containing PPA in the lower dose (50 mg) taken twice a day in a cross-over, double-blind study significantly reduced nasal obstruction, secretion, and sneezing compared with placebo. Side effects of PPA are discussed.
D000293:Adolescent; D000328:Adult; D000403:Airway Resistance / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001977:Brompheniramine / Q000008:administration & dosage; D004087:Dihydroergotamine / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010665:Phenylpropanolamine / Q000008:administration & dosage; D011674:Pulse / Q000187:drug effects; D012223:Rhinitis, Vasomotor / Q000188:drug therapy* / Q000503:physiopathology; D014662:Vasoconstrictor Agents / Q000008:administration & dosage*
D004338:Drug Combinations; D014662:Vasoconstrictor Agents; D010665:Phenylpropanolamine; D004087:Dihydroergotamine; D001977:Brompheniramine